CAR-T therapies are currently less effective in AML, but ATRA increases the expression of CD38 on the cell surface of AML cells, thereby increasing the efficacy of CD38-CAR-T for AML (Yoshida et al., 2016). Here, CD38 is linked to acute myeloid leukemia.